Purchases are not available yet. You can browse the site and sign in.
Psilocybin Retreat Contraindications: Who Should Not Go · Microdosing College
Retreats
Who Should Not Do a Psilocybin Retreat: Contraindications Explained
By Microdosing College Editorial·Last updated July 3, 2026·8 min read
Psilocybin retreat contraindications are among the most important — and most under-discussed — topics in psychedelic education. A retreat involves a full ceremonial dose of psilocybin, not a microdose: effects are strong, last four to six hours according to the European Union Drugs Agency (EUDA, Hallucinogenic Mushrooms Drug Profile), and take place in a group or semi-group setting where emergency medical care is rarely on-site. That combination means the stakes of poor screening are high.
This article outlines the personal history factors, medical conditions, and medications that lead responsible centres to exclude applicants — and explains why those exclusions exist. It is not a clinical assessment. If you are unsure whether any of the factors below apply to you, use our and consult a qualified clinician before taking any further steps. You may also want to read our companion piece on , which covers how well-run centres conduct their intake process.
Psychiatric History: The Single Largest Risk Factor
The most consistently cited contraindication across clinical research and harm-reduction frameworks is a personal or family history of psychosis, schizophrenia, or bipolar disorder with psychotic features.
Psilocybin is a serotonin 2A receptor agonist. In individuals with a genetic vulnerability to psychotic or manic episodes, high-dose administration has been associated with triggering or prolonging those states — sometimes requiring psychiatric hospitalisation. Johnson, Richards, and Griffiths (2008), whose safety guidelines for human hallucinogen research remain the most widely cited framework in the field, list "personal or family history of psychosis or serious psychiatric history" as a primary exclusion criterion for psilocybin administration (Johnson et al., 2008, Journal of Psychopharmacology).
The same framework flags current moderate-to-severe depression or anxiety not as an absolute contraindication, but as a factor requiring individual clinical judgment and close professional support — conditions that most retreat settings, which are not clinical trials, cannot adequately provide.
This is not a value judgment about people with these diagnoses. It reflects a specific pharmacological reality: the same mechanisms that can produce insight and emotional openness at a full dose can, in vulnerable individuals, produce destabilisation that is difficult to contain outside a clinical setting.
Practical implication: If you have ever been diagnosed with schizophrenia, schizoaffective disorder, or bipolar I or II disorder, or if a first-degree relative has, disclose this fully on any retreat application. Reputable centres will ask — and those that do not ask are a warning sign in themselves.
Cardiovascular and Other Medical Conditions
Psilocybin produces a transient increase in heart rate and blood pressure during the acute phase of experience. For most healthy adults this is not clinically significant. For people with certain cardiovascular conditions it introduces meaningful risk.
Conditions that commonly appear on exclusion lists include:
Serious cardiac arrhythmias, particularly those requiring medication management
Uncontrolled hypertension (high blood pressure)
Recent cardiac events — heart attack or major cardiac surgery within the preceding months
Severe liver disease, given that psilocybin is hepatically metabolised
A full-dose psilocybin experience also involves significant physiological activation: raised body temperature, potential nausea and vomiting, and prolonged periods of physical stillness that may not suit people with musculoskeletal or mobility conditions. None of these are disqualifying on their own, but they are part of the picture a good medical screener will consider.
If you have any active cardiovascular diagnosis or are being treated for a chronic physical condition, a conversation with your GP or cardiologist before applying to a retreat is not optional — it is the minimum responsible step.
Medications: The Interaction Risk Most People Underestimate
Medication interactions are arguably the most underappreciated category of psilocybin retreat contraindications. Many people assume that because they feel well on their current medication, a short psilocybin experience will simply layer on top without consequence. The pharmacology does not support that assumption.
Lithium carries the most serious known interaction risk. Case reports and clinical literature document an increased risk of seizures when lithium is combined with classic psychedelics, including psilocybin. Johnson et al. (2008) explicitly identify lithium as a contraindicated concurrent medication in their safety framework. Anyone taking lithium for bipolar disorder should consider this an absolute exclusion unless advised otherwise by a specialist psychiatrist with specific expertise in psychedelic medicine.
SSRIs and SNRIs (selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) present a more nuanced picture. Chronic SSRI use has been associated with reduced subjective effects of psilocybin, which creates its own problems: a participant may require a higher-than-standard dose to feel any effect, or may feel unexpectedly little and be tempted to redose unsafely. There is also a theoretical serotonin syndrome risk, though this appears to be relatively low with psilocybin specifically. The core issue is that the SSRI interaction profile makes predictable dosing and a predictable experience much harder.
MAOIs (monoamine oxidase inhibitors) significantly potentiate serotonergic activity and can produce severe serotonin toxicity when combined with psychedelics. This interaction is well-documented and MAOIs represent a hard exclusion at virtually all serious retreat programmes.
Tramadol, a synthetic opioid that also has serotonergic activity, carries a similar profile to MAOIs in terms of serotonin risk and should be considered incompatible with full-dose psilocybin.
Other medication classes worth flagging to a screener include antipsychotics (which pharmacologically oppose psilocybin's mechanism), anticonvulsants, and beta-blockers (cardiovascular interactions). The list is not exhaustive, and the field's understanding of these interactions is still developing.
If you take any prescribed psychiatric or cardiovascular medication, provide the complete list — including dose and duration — to any retreat you are considering. A centre that accepts you without asking is not a centre you should trust.
For a broader look at medication and health considerations in a lower-dose context, our microdosing contraindications guide covers much of the same pharmacological ground and is a useful complement to this article.
Psychological Vulnerability and Life Circumstances
Not all contraindications are medical. The research literature and experienced facilitators consistently identify a cluster of psychological and circumstantial factors that increase the likelihood of a difficult or harmful experience.
Bienemann et al. (2020) conducted a textual analysis of 346 self-reported negative psilocybin experiences in naturalistic settings — outside clinical supervision — and found that pre-existing psychological distress and an unsupportive setting were among the factors most strongly associated with sustained negative outcomes (Bienemann et al., 2020, PLOS ONE). Carbonaro et al. (2016) surveyed 1,993 people about their most challenging psilocybin experience and found that 39% rated it among the most difficult experiences of their life, with difficulty correlating with dose (Carbonaro et al., 2016, Journal of Psychopharmacology).
Reputable centres often delay or decline applicants who are:
In acute grief or crisis — a fresh bereavement, recent separation, or active trauma processing without therapeutic support
Under significant ongoing life stress — a major financial crisis, pending legal proceedings, or relationship breakdown
Motivated primarily by escape rather than curiosity or intentional work
Unable or unwilling to engage with preparation and integration — both of which require time and a degree of psychological stability
None of these make someone a "bad candidate" permanently. They often point toward readiness: returning to a retreat application after stabilisation and some therapeutic support is almost always the wiser path.
What Good Screening Looks Like — and Why It Matters
A responsible retreat will conduct a substantive screening process before accepting any applicant. This typically includes a written medical and psychiatric history questionnaire, a one-to-one call or video interview with a facilitator or medical advisor, and often a request to consult your GP if any flag appears.
Screening is not a bureaucratic hurdle. It is the mechanism that connects the exclusion criteria above to actual safety outcomes. Johnson et al. (2008) make clear that preparation, informed consent, and careful participant selection are not separable from the safety of the experience itself — they are part of what makes the difference between a supported, contained journey and an adverse event.
If you are uncertain whether any of the factors in this article apply to you, the right first step is our self-screener — not an application form.
Frequently asked
Can I do a psilocybin retreat if I take antidepressants?+
It depends on the specific medication. SSRIs may reduce psilocybin's effects and complicate dosing; MAOIs carry a serious serotonin toxicity risk and are a hard exclusion. Disclose all medications to the retreat centre and consult your prescribing doctor before applying — do not stop any medication without medical supervision.
Is a family history of schizophrenia a contraindication for a retreat?+
Yes, in most clinical and harm-reduction frameworks. Johnson, Richards and Griffiths (2008) identify family history of psychosis as a primary exclusion criterion for high-dose psilocybin. A first-degree relative with schizophrenia or schizoaffective disorder indicates potential genetic vulnerability and should be disclosed on any application.
Can someone with a heart condition attend a psilocybin retreat?+
Serious arrhythmias, uncontrolled hypertension, and recent cardiac events are common exclusion criteria because psilocybin transiently raises heart rate and blood pressure. Anyone with a cardiovascular diagnosis should obtain medical clearance from their cardiologist before applying to any retreat programme.
What if a retreat does not ask about my medical history?+
That is a significant warning sign. Responsible centres always conduct a medical and psychiatric screening process. A centre that accepts you without asking about medications, psychiatric history, or cardiovascular health is not following established safety guidelines and should not be trusted with your wellbeing.
Are there psychological reasons — not medical — to postpone a retreat?+
Yes. Acute grief, active trauma without therapeutic support, major ongoing life stress, or a desire to 'escape' rather than engage are all reasons many experienced facilitators recommend postponing. Psychological stability before a session is part of what makes the experience safe and productive, not just physical health.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
